{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:32:04Z","timestamp":1790789524426,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.lungcan.2023.01.017","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T11:34:17Z","timestamp":1675251257000},"page":"66-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3160-5403","authenticated-orcid":false,"given":"Jin","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Mei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weineng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7154-8928","authenticated-orcid":false,"given":"Jun-Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-6731","authenticated-orcid":false,"given":"Chun-wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8498-0119","authenticated-orcid":false,"given":"Jin-Ji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2021","key":"10.1016\/j.lungcan.2023.01.017_b0005","first-page":"7","article-title":"CA Cancer","volume":"71","author":"Siegel","year":"2021","journal-title":"J. Clin."},{"key":"10.1016\/j.lungcan.2023.01.017_b0010","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - Molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.017_b0015","doi-asserted-by":"crossref","unstructured":"G. Recondo, J. Che, P.A. J\u00e4nne, M.M. Awad, Targeting MET dysregulation in cancer, Cancer Discov. 10 (2020) 922\u2013934. 10.1158\/2159-8290.CD-19-1446.","DOI":"10.1158\/2159-8290.CD-19-1446"},{"key":"10.1016\/j.lungcan.2023.01.017_b0020","doi-asserted-by":"crossref","unstructured":"E.Y. Rosen, M.L. Johnson, S.E. Clifford, R. Somwar, J.F. Kherani, J. Son, A.A. Bertram, M.A. Davare, E. Gladstone, E.V. Ivanova, D.N. Henry, E.M. Kelley, M. Lin, M.S.D. Milan, B.C. Nair, E.A. Olek, J.E. Scanlon, M. Vojnic, K. Ebata, J.F. Hechtman, B.T. Li, L.M. Sholl, B.S. Taylor, M. Ladanyi, P.A. J\u00e4nne, S.M. Rothenberg, A. Drilon, G.R. Oxnard, Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib, Clin. Cancer Res. 27 (2021) 34\u201342. 10.1158\/1078-0432.CCR-20-2278.","DOI":"10.1158\/1078-0432.CCR-20-2278"},{"key":"10.1016\/j.lungcan.2023.01.017_b0025","doi-asserted-by":"crossref","unstructured":"I. Dagogo-Jack, S. Yoda, J.K. Lennerz, A. Langenbucher, J.J. Lin, M.M. Rooney, K. Prutisto-Chang, A. Oh, N.A. Adams, B.Y. Yeap, E. Chin, A. Do, H.D. Marble, S.E. Stevens, S.R. Digumarthy, A. Saxena, R.J. Nagy, C.H. Benes, C.G. Azzoli, M.S. Lawrence, J.F. Gainor, A.T. Shaw, A.N. Hata, MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer, Clin. Cancer Res. 26 (2020) 2535\u20132545. 10.1158\/1078-0432.CCR-19-3906.","DOI":"10.1158\/1078-0432.CCR-19-3906"},{"key":"10.1016\/j.lungcan.2023.01.017_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100319","article-title":"Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer","volume":"6","author":"Coleman","year":"2021","journal-title":"ESMO Open."},{"key":"10.1016\/j.lungcan.2023.01.017_b0035","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/nm.4204","article-title":"Recurrent MET fusion genes represent a drug target in pediatric glioblastoma","volume":"22","author":"International Cancer Genome Consortium PedBrain Tumor Project","year":"2016","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2023.01.017_b0040","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pulmoe.2022.02.001","article-title":"KIF5B-MET fusion variant in non-small cell lung cancer","volume":"28","author":"Costa","year":"2022","journal-title":"Pulmonology"},{"key":"10.1016\/j.lungcan.2023.01.017_b0045","article-title":"Case report: Dramatic response to crizotinib in a patient with non-small cell lung cancer positive for a novel ARL1-MET fusion","volume":"12","author":"Ma","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.017_b0050","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.cell.2018.09.038","article-title":"Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor","volume":"175","author":"Hu","year":"2018","journal-title":"Cell."},{"key":"10.1016\/j.lungcan.2023.01.017_b0055","article-title":"Dramatic response to crizotinib in a patient with lung cancer positive for an HLA-DRB1-MET gene fusion","volume":"2017","author":"Davies","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.017_b0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2020.04.040","article-title":"Analysis of MET kinase domain rearrangement in NSCLC","volume":"145","author":"Zhuo","year":"2020","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2023.01.017_b0065","doi-asserted-by":"crossref","unstructured":"D. Plenker, M. Bertrand, A.J. de Langen, R. Riedel, C. Lorenz, A.H. Scheel, J. M\u00fcller, J. Br\u00e4gelmann, J. Da\u00dfler-Plenker, C. Kobe, T. Persigehl, A. Kluge, T. Wurdinger, P. Schellen, G. Hartmann, T. Zacherle, R. Menon, E. Thunnissen, R. B\u00fcttner, F. Griesinger, J. Wolf, L. Heukamp, M.L. Sos, J.M. Heuckmann, Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients, Clin. Cancer Res. 24 (2018) 1337\u20131343. 10.1158\/1078-0432.CCR-17-3001.","DOI":"10.1158\/1078-0432.CCR-17-3001"},{"key":"10.1016\/j.lungcan.2023.01.017_b0070","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.jtho.2018.10.160","article-title":"Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung adenocarcinoma following Treatment with erlotinib and Osimertinib","volume":"14","author":"Nelson","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.017_b0075","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/j.jtho.2019.01.025","article-title":"A novel CAV1-MET fusion in SCLC transformation responds to crizotinib and osimertinib treatment","volume":"14","author":"Liu","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.017_b0080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA approval summary: Capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET Exon 14 skipping mutations or alterations","volume":"28","author":"Mathieu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2023.01.017_b0085","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","article-title":"Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: A multicentre, single-arm, open-label, phase 2 study","volume":"9","author":"Lu","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2023.01.017_b0090","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jtho.2016.05.016","article-title":"The unique characteristics of MET Exon 14 mutation in Chinese patients with NSCLC","volume":"11","author":"Liu","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.017_b0095","first-page":"2279","article-title":"Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients, Thorac","volume":"11","author":"Chen","year":"2020","journal-title":"Cancer."},{"key":"10.1016\/j.lungcan.2023.01.017_b0100","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1038\/s41467-021-23379-3","article-title":"Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics","volume":"12","author":"Ding","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2023.01.017_b0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cllc.2021.08.009","article-title":"PD-L1 expression and comprehensive molecular profiling predict survival in nonsmall cell lung cancer: A real-world study of a Large Chinese cohort","volume":"23","author":"Jin","year":"2022","journal-title":"Clin. Lung Cancer."},{"key":"10.1016\/j.lungcan.2023.01.017_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.08.451","article-title":"MA16.05 MET kinase domain rearrangements (KDRE) in non-small cell lung cancer (NSCLC) identified through comprehensive genomic profiling (CGP)","volume":"13","author":"Schrock","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.017_b0115","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.str.2017.04.015","article-title":"Structural basis of TPR-mediated oligomerization and activation of oncogenic fusion kinases","volume":"25","author":"Pal","year":"2017","journal-title":"Structure."},{"key":"10.1016\/j.lungcan.2023.01.017_b0120","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jtho.2019.06.023","article-title":"Sensitivity and resistance of MET Exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro","volume":"14","author":"Fujino","year":"2019","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300048X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300048X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:00Z","timestamp":1759237500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022300048X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":24,"alternative-id":["S016950022300048X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.01.017","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}